echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zuoli Pharmaceutical Polycarbophil Calcium Tablets Obtained Drug Registration Certificate

    Zuoli Pharmaceutical Polycarbophil Calcium Tablets Obtained Drug Registration Certificate

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 9, Zuoli Pharmaceuticals issued an announcement stating that the company received the "Drug Registration Certificate" for polycarbophil calcium tablets approved and issued by the National Medical Products Administration for the relief of patients with irritable bowel syndrome (constipation).


    The polycarbophil calcium tablets of Zuoli Pharmaceuticals are researched and developed using Polyful® from Mylan Company of Japan as the reference drug.


    Polycarbophil calcium, the active ingredient in polycarbophil calcium tablets, has very unique biochemical properties.


    Polycarbophil calcium itself is an inert, non-absorbable high molecular polymer.


    In addition, polycarbophil calcium tablets and Wuling capsules have a certain synergistic effect in the application of gastroenterology


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.